Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Elesta S.R.L. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The goal of this prospective study is to test the efficacy of Echolaser transperineal focal therapy in patients with low- and intermediate risk prostate cancer. The main question it aims to answer are: 1. short and intermediate term oncological outcomes after laser focal therapy, 2. functional outcomes and quality of life after treatment. Participants affected by low risk prostate cancer will undergo trans perineal laser focal therapy. Multiparametric prostate MRI will be perform after 3 and 12 months for oncological control. Re-fusion biopsy will be perform after 12 months. Functional outcomes and quality of life will be assess at 3, 6 and 12 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TPLA in patients with prostate cancer | Experimental | Patients diagnosed with low- and intermediate risk unifocal prostate cancer undergo to focal laser ablation therapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Soractelite Echolaser Transperineal focal laser ablation | Procedure | US/MRI fusion laser ablation of low- and intermediate risk prostate cancer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Oncological outcomes MRI | Evaluation of transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by multiparametric prostate MRI. Specifically, 1. complete ablation, 2. partial ablation or 3. persistence of cancer will be identified. | 3 months after treatment |
| Oncological outcomes MRI | Evaluation of transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by multiparametric prostate MRI. Specifically, 1. complete ablation, 2. partial ablation or 3. persistence of cancer will be identified. | 12 months after treatment |
| Oncological outcomes PSA | Evaluation of transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by eventual reduction of PSA. | 3 months after treatment. |
| Oncological outcomes PSA | Evaluation of transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by eventual reduction of PSA. | 6 months after treatment. |
| Oncological outcomes PSA | Evaluation of transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by eventual reduction of PSA. | 12 months after treatment. |
| Oncological outcomes Re-biopsy | Evaluation of histological outcomes after transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by eventual negativity for cancer in a re-biopsy. |
| Measure | Description | Time Frame |
|---|---|---|
| Functional outcomes IPSS and IPSS QoL | Evaluation of lower urinary tract symptoms and quality of life after transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by the IPSS, International Prostatic Symptoms Score. | 3, 6 and 12 months after treatment. |
| Quality of life Pain |
Not provided
Inclusion Criteria:
Exclusion Criteria:
The trial is conducted on a population of males who underwent surgical intervention for prostate cancer.
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Valerio Iacovelli, MD, PhD | Contact | +393398461654 | valerio.iacovelli85@gmail.com | |
| Pierluigi Bove, MD | Contact | pgbove@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Pierluigi Bove, MD | San Carlo di Nancy Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| San Carlo di Nancy Hospital | Recruiting | Roma | RM | 00175 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35528781 | Result | van Riel LAMJG, van Kollenburg RAA, Vis AN, van Leeuwen PJ, de Reijke TM, de Bruin DM, Oddens JR. Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. Eur Urol Open Sci. 2022 Apr 2;39:48-54. doi: 10.1016/j.euros.2022.02.012. eCollection 2022 May. |
Not provided
Not provided
The analysis of the data obtained within the trial will be subject of scientific publication
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 months after treatment |
Evaluation of pain after transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by the visual analogue scale (VAS). The VAS is a straight horizontal line of fixed length. The ends are defined as the extreme limits of the parameter to be measured (pain) from 0 to 10 orientated from the left (no pain) to the right (unbearable pain). |
| day after surgery |
| Functional outcomes Continence | Evaluation of continence rate after transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by the ICIQ-SF, International Consulation on Incontinence Questionnaire - Short Form. | 3, 6 and 12 months after treatment. |
| Functional outcomes Erection | Evaluation of erectile function after transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by the IIEF5, International Index of Erectile Function. | 3, 6 and 12 months after treatment. |
| Functional outcomes Ejaculation | Evaluation of ejaculatory function after transperineal laser focal therapy on unifocal low- and intermediate risk prostate cancer as assessed by the MSHQ SF, Male Sexual Health Questionnaire short form. | 3, 6 and 12 months after treatment. |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |